Statin Therapy and Intensities for Cardiovascular Disease Prevention

For these patients, the goal is not just "lowering cholesterol," but rather preventing a second, potentially fatal event. Consequently, secondary prevention almost always requires more aggressive, high-intensity statin therapy.

Exam Tip: If a question mentions a patient has had a "previous MI" or "stroke," immediately categorize them under Secondary Prevention. They are high-risk and will likely require high-intensity therapy.

Statin Intensities: Low vs. High

Statins are categorized by their "intensity," which refers to their ability to lower Low-Density Lipoprotein (LDL) cholesterol. The intensity is determined by the dose and the specific type of statin used.

High-Intensity Statins

High-intensity statins are designed to achieve a significant reduction in LDL cholesterol—specifically, a reduction of $\geq 50\%$ from the baseline. These are typically reserved for:

• Patients with established ASCVD (Secondary Prevention).
• Patients with very high LDL levels (e.g., $\geq 190$ mg/dL) regardless of other risk factors.
• Patients with diabetes and multiple high-risk factors.

Common High-Intensity Examples:

• Atorvastatin (40–80 mg)
• Rosuvastatin (20–40 mg)

Low-to-Moderate Intensity Statins

Low-intensity statins are used when the goal is a more modest reduction in LDL (typically $< 30\%$ reduction). These may be used for patients in primary prevention with low-to-intermediate risk scores, or for patients who cannot tolerate high-intensity doses due to side effects.

Common Low-to-Moderate Examples:

• Simvastatin (10–40 mg)
• Pravastatin (10–40 mg)
• Lovastatin (20–40 mg)
• Atorvastatin (10 mg is considered low-intensity)

Clinical Decision-Making: A Worked Example

To solidify these concepts, let's look at two hypothetical patient scenarios.

Scenario A: A 55-year-old male presents for a routine physical. He has hypertension and Type 2 Diabetes but has never had a heart attack or stroke. His LDL is 130 mg/dL.

• Category: Primary Prevention (no prior event).
• Approach: Calculate ASCVD risk. Depending on the risk score, he may be started on moderate-intensity statin therapy to prevent a future event.

Scenario B: A 62-year-old female presents for follow-up. She underwent stent placement two years ago following an acute myocardial infarction. Her LDL is 110 mg/dL.

• Category: Secondary Prevention (history of MI).
• Approach: Even though her LDL is not extremely high, her history of ASCVD mandates high-intensity statin therapy to prevent a recurrent event.

Monitoring and Side Effects

While statins are highly effective, they are not without risks. When managing intensity, clinicians must monitor for:

1. Muscle Symptoms (SAMS): Statin-associated muscle symptoms, ranging from mild myalgia (pain without weakness) to rare but serious rhabdomyolysis (muscle breakdown).
2. Liver Enzymes: While rare, clinicians may monitor liver function tests (LFTs) to ensure the medication is not causing hepatic injury.
3. Blood Glucose: There is a slight association between statin use and an increased risk of developing Type 2 Diabetes, though the cardiovascular benefits generally outweigh this risk.

Clinical Pearl: If a patient reports new-onset muscle pain or weakness after starting a high-intensity statin, the first step is often to assess for Creatine Kinase (CK) levels and evaluate the need for a dose reduction or a switch to a different statin.